VirnetX Holding Corporation — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021; unaudited. VirnetX develops secure communications products and seeks to monetize its patent portfolio through licensing and litigation. Its GABRIEL platform and related products generated very little reported revenue this quarter.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Revenue | $5,000 | $302.576 million |
| Operating expenses | $33.657 million | $119.382 million |
| Operating income (loss) | $(33.652) million | $183.194 million |
| Net income (loss) | $(26.443) million | $299.945 million |
| Basic and diluted EPS | $(0.37) | $4.26 / $4.20 |
| Cash from operations | $(4.225) million | $426.360 million |
Quarter-end cash and cash equivalents were $197.198 million, with $19.835 million of available-for-sale investments. Company-reported working capital was $181.405 million. Total assets were $237.996 million and total stockholders’ equity was $198.875 million. The balance sheet reports no debt. No meaningful revenue margin comparison is available given the minimal 2021 revenue and the one-time litigation-related revenue in 2020.
Changes versus the prior-year quarter
- Revenue fell from $302.576 million to $5,000. The 2020 quarter included $302.428 million of Apple-related royalties recognized from a $454.034 million payment received in March 2020.
- Q1 2020 also included $41.271 million of settlement gain and $108.221 million of Apple-related interest income. These items did not recur in Q1 2021.
- Q1 2021 SG&A rose $14.567 million to $41.943 million, primarily reflecting a $38.284 million accrued McKool Smith legal award, partly offset by lower attorney fees. R&D decreased $753,000 to $1.152 million.
- Licensing costs were a $9.438 million credit in Q1 2021, reflecting reversal of previously accrued costs associated with the McKool award; Q1 2020 included $90.101 million in licensing costs.
Outlook, litigation and risks
- Management says cash and short-term investments should fund current SG&A, legal costs and working capital for the foreseeable future. It expects longer-term revenue primarily from patent portfolio, technology and software licenses and royalties, but gives no quantified revenue or earnings guidance.
- The Apple II jury awarded VirnetX $502.8 million in October 2020; the district court denied Apple’s post-trial motion in January 2021, and Apple appealed in February. The award had not been collected or recognized as a contingent gain at quarter-end. Patent challenges and appeals could delay, reduce or eliminate any recovery.
- McKool Smith’s arbitration award of $36.323 million plus interest was issued April 19, 2021. VirnetX had accrued $38.284 million at March 31 and paid it April 20; the matter is closed.
- Management highlights risks from uncertain litigation and patent validity, limited licensing and product revenue, long and unpredictable sales cycles, customer concentration, commercialization challenges, and COVID-19-related disruption. Some patents expire between 2021 and 2034.
- Management reported disclosure controls were effective as of March 31, 2021, with no material changes in internal control over financial reporting. No off-balance-sheet arrangements were reported.
Key facts for investors to verify
- Current status and outcome of Apple II appeals and related patent-validity challenges; the verdict is not cash or recognized revenue.
- Actual future licensing and product revenue, given Q1 revenue of only $5,000 and management’s reliance on licensing and royalties.
- Legal expense exposure and the treatment of future litigation awards, fees and cost reimbursements.
- Cash, investment balances and operating cash use, alongside the company’s stated liquidity runway.
- Patent expiration dates and any effects of adverse court or patent-office decisions on the portfolio’s value.